Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Valbenazine in Tourette Syndrome
NCT02879578Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Jul 2016
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of valbenazine in Tourette syndrome (TS) (3 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Frequency of Treatment-emergent Adverse Events at 28 weeks. Started Jul 2016; status: completed.
02
Drugs
valbenazine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NCT02879578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02879578.